Group One Trading, L.P. Intellia Therapeutics, Inc. Transaction History

Group One Trading, L.P.

$3.01 Billion
Q2 2024

A detailed history of Group One Trading, L.P. transactions in Intellia Therapeutics, Inc. stock. As of the latest transaction made, Group One Trading, L.P. holds 8,631 shares of NTLA stock, worth $138,096. This represents 0.01% of its overall portfolio holdings.

Number of Shares

8,631

Holding current value

$138,096

% of portfolio

0.01%

23 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$20.02 - $27.22 $172,792 - $234,935	8,631 New	8,631 $193,000
Q4 2023 Feb 14, 2024	BUY	$23.16 - $32.34 $158,067 - $220,720	6,825 Added 146.62%	11,480 $350,000
Q3 2023 Nov 09, 2023	SELL	$31.62 - $45.78 $150,226 - $217,500	-4,751 Reduced 50.51%	4,655 $147,000
Q2 2023 Aug 09, 2023	BUY	$34.58 - $46.03 $325,259 - $432,958	9,406 New	9,406 $383,000
Q4 2022 Feb 09, 2023	BUY	$33.21 - $62.69 $437,309 - $825,501	13,168 New	13,168 $459,000
Q2 2022 Aug 11, 2022	BUY	$38.49 - $76.21 $1.04 Million - $2.05 Million	26,901 New	26,901 $1.39 Million
Q3 2021 Nov 12, 2021	SELL	$132.37 - $176.78 $3.73 Million - $4.99 Million	-28,210 Closed	0 $0
Q2 2021 Aug 10, 2021	BUY	$60.88 - $161.91 $756,312 - $2.01 Million	12,423 Added 78.69%	28,210 $4.57 Million
Q1 2021 May 12, 2021	BUY	$46.59 - $83.68 $447,823 - $804,332	9,612 Added 155.66%	15,787 $1.27 Million
Q4 2020 Feb 10, 2021	BUY	$18.83 - $63.53 $116,275 - $392,297	6,175 New	6,175 $336,000
Q2 2020 Aug 13, 2020	SELL	$11.14 - $22.87 $131,953 - $270,895	-11,845 Closed	0 $0
Q1 2020 May 13, 2020	BUY	$9.44 - $15.58 $22,571 - $37,251	2,391 Added 25.29%	11,845 $145,000
Q4 2019 Feb 10, 2020	SELL	$10.43 - $17.67 $20,328 - $34,438	-1,949 Reduced 17.09%	9,454 $139,000
Q3 2019 Nov 12, 2019	BUY	$13.07 - $18.51 $134,150 - $189,986	10,264 Added 901.14%	11,403 $152,000
Q2 2019 Aug 09, 2019	SELL	$13.88 - $18.41 $74,952 - $99,414	-5,400 Reduced 82.58%	1,139 $19,000
Q1 2019 May 13, 2019	BUY	$12.79 - $17.62 $10,232 - $14,096	800 Added 13.94%	6,539 $112,000
Q4 2018 Feb 06, 2019	BUY	$11.39 - $27.13 $39,329 - $93,679	3,453 Added 151.05%	5,739 $78,000
Q3 2018 Nov 08, 2018	SELL	$25.78 - $32.6 $254,912 - $322,348	-9,888 Reduced 81.22%	2,286 $65,000
Q2 2018 Aug 14, 2018	SELL	$20.02 - $30.79 $1.48 Million - $2.28 Million	-73,916 Reduced 85.86%	12,174 $333,000
Q1 2018 May 11, 2018	BUY	$19.43 - $34.95 $917,542 - $1.65 Million	47,223 Added 121.5%	86,090 $1.82 Million
Q4 2017 Feb 09, 2018	BUY	$17.39 - $31.12 $543,646 - $972,873	31,262 Added 411.07%	38,867 $747,000
Q3 2017 Nov 15, 2017	SELL	$15.16 - $25.75 $87,427 - $148,500	-5,767 Reduced 43.13%	7,605 $189,000
Q2 2017 Aug 14, 2017	BUY	N/A	13,372	13,372 $214,000

Others Institutions Holding NTLA

# of Institutions

318

Shares Held

88.5M

Call Options Held

668K

Put Options Held

865K

View Full List

About Intellia Therapeutics, Inc.

Ticker NTLA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,011,800
Market Cap $1.22B
Description
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...

More about NTLA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Group One Trading, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Group One Trading, L.P. with notifications on news.

Account

Group One Trading, L.P. Intellia Therapeutics, Inc. Transaction History